Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polvac is a prominent brand of veterinary vaccines primarily developed and marketed by Zoetis (formerly Pfizer Animal Health). The product line encompasses a wide range of inactivated bacterial vaccines (bacterins) and toxoids designed to protect livestock and poultry against various infectious diseases. Key products within the line include Polvac C, which targets *Clostridium chauvoei* (Blackleg); Polvac S, an inactivated vaccine for *Salmonella typhimurium* and *Salmonella enteritidis* in poultry; and Polvac 7-in-1, a combination vaccine for cattle providing protection against five clostridial species and two *Leptospira* serovars. The mechanism of action involves the presentation of inactivated bacterial antigens or toxoids to the animal's immune system, stimulating the production of specific antibodies and memory cells to provide active immunity against subsequent natural exposure. The brand is particularly well-established in the Australian and New Zealand agricultural markets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Polvac.